|
NZ601880A
(en)
*
|
2007-11-01 |
2013-12-20 |
Univ Arkansas |
Compositions and methods of enhancing immune responses to eimeria
|
|
WO2010003766A2
(en)
|
2008-06-17 |
2010-01-14 |
Apogenix Gmbh |
Multimeric tnf receptors
|
|
HUE025236T2
(en)
|
2008-07-21 |
2016-03-29 |
Apogenix Gmbh |
TNFSF single chain molecules
|
|
EP2370068A4
(en)
|
2008-12-10 |
2015-09-23 |
Paka Pulmonary Pharmaceuticals Inc |
METHOD AND COMPOSITIONS FOR DELIVERING MEDICAMENTS TO THE LUNG
|
|
EP2829550B1
(en)
*
|
2009-01-09 |
2016-11-16 |
Apogenix AG |
Fusion proteins forming trimers
|
|
CN101698852B
(zh)
*
|
2009-10-23 |
2014-08-13 |
江苏先声药物研究有限公司 |
具有cd137l功能的蛋白或多肽及其基因和应用
|
|
WO2011105537A1
(ja)
*
|
2010-02-26 |
2011-09-01 |
積水メディカル株式会社 |
偽陽性反応を抑制する検体抽出液
|
|
WO2012040101A1
(en)
|
2010-09-21 |
2012-03-29 |
University Of Miami |
Compositions and methods for inducing migration by dendritic cells and an immune response
|
|
WO2012040266A2
(en)
*
|
2010-09-24 |
2012-03-29 |
University Of Miami |
Gene-based adjuvants and compositions thereof to increase antibody production in response to gene-based vaccines
|
|
US9161991B2
(en)
*
|
2010-12-03 |
2015-10-20 |
Adamed Sp. Z O. O. |
Anticancer fusion protein comprising TRAIL and interferon
|
|
EP2586793A1
(en)
|
2011-10-27 |
2013-05-01 |
Centre National de la Recherche Scientifique |
Chimeric molecule involving oligomerized FasL extracellular domain
|
|
JP6152379B2
(ja)
*
|
2012-06-29 |
2017-06-21 |
旭化成メディカル株式会社 |
プロテインａのｂドメイン変異体を含むポリペプチドが結合された担体からなる吸着材
|
|
NO2776305T3
(enExample)
|
2014-04-23 |
2018-01-27 |
|
|
|
WO2016079527A1
(en)
|
2014-11-19 |
2016-05-26 |
Tetralogic Birinapant Uk Ltd |
Combination therapy
|
|
WO2016097773A1
(en)
|
2014-12-19 |
2016-06-23 |
Children's Cancer Institute |
Therapeutic iap antagonists for treating proliferative disorders
|
|
MA41460A
(fr)
|
2015-02-03 |
2017-12-12 |
Oncomed Pharm Inc |
Agents de liaison à la tnfrsf et leurs utilisations
|
|
ES2907486T3
(es)
*
|
2015-09-24 |
2022-04-25 |
Univ North Carolina Chapel Hill |
Métodos y composiciones para reducir metástasis
|
|
CA3002741A1
(en)
|
2015-10-23 |
2017-04-27 |
Apogenix Ag |
Single-chain gitr-receptor agonist proteins
|
|
WO2017072080A1
(en)
*
|
2015-10-28 |
2017-05-04 |
Apogenix Ag |
Single-chain tl1a receptor agonist proteins
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
JP7664020B2
(ja)
|
2017-01-06 |
2025-04-17 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
カリウムチャネルアゴニストによる腫瘍浸潤リンパ球の増殖及びその治療的使用
|
|
BR112019013940A2
(pt)
|
2017-01-06 |
2020-02-11 |
Iovance Biotherapeutics, Inc. |
Método de tratar um câncer com uma população de linfócitos infiltrantes de tumor, processo para preparação de uma população de linfócitos infiltrantes de tumor, população de linfócitos infiltrantes de tumor, e, composição farmacêutica.
|
|
JP7370580B2
(ja)
|
2017-04-06 |
2023-10-30 |
ウニヴェルズィテート シュトゥットガルト |
結合および生物活性を改善した腫瘍壊死因子受容体（ｔｎｆｒ）結合タンパク質複合体
|
|
BR112019023409A2
(pt)
|
2017-05-10 |
2020-06-16 |
Iovance Biotherapeutics, Inc. |
Métodos para tratar um câncer em um paciente e uma malignidade hematológica, para expandir linfócitos infiltrantes de tumor, linfócitos de sangue periférico e linfócitos infiltrantes de medula, processo para a preparação de uma população de linfócitos infiltrantes de tumor, e, uso de um tumor líquido na fabricação de uma população de linfócitos infiltrantes de tumor.
|
|
TW201919662A
(zh)
|
2017-06-05 |
2019-06-01 |
美商艾歐凡斯生物治療公司 |
對雙重難治性黑色素瘤使用腫瘤浸潤性淋巴細胞之方法
|
|
AU2018359420A1
(en)
|
2017-10-31 |
2020-06-04 |
Kalivir Immunotherapeutics, Inc. |
Platform oncolytic vector for systemic delivery
|
|
CR20200251A
(es)
|
2017-11-17 |
2020-07-17 |
Iovance Biotherapeutics Inc |
Expansión de til de aspirados con aguja fina y biopsias por punción
|
|
EP3714041A1
(en)
|
2017-11-22 |
2020-09-30 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
|
JP7565795B2
(ja)
|
2017-12-15 |
2024-10-11 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
腫瘍浸潤リンパ球の有益な投与を決定するシステム及び方法並びにその使用方法、並びに腫瘍浸潤リンパ球の有益な投与及びその使用方法
|
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
US11713446B2
(en)
|
2018-01-08 |
2023-08-01 |
Iovance Biotherapeutics, Inc. |
Processes for generating TIL products enriched for tumor antigen-specific T-cells
|
|
KR20200119242A
(ko)
|
2018-01-08 |
2020-10-19 |
이오반스 바이오테라퓨틱스, 인크. |
종양 항원-특이적 t-세포에 대해 풍부화된 til 생성물의 생성 방법
|
|
US20210137930A1
(en)
|
2018-02-13 |
2021-05-13 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
|
|
BR112020019496A2
(pt)
|
2018-03-29 |
2021-01-12 |
Iovance Biotherapeutics, Inc. |
Método para expandir linfócitos infiltrando os tumores, população de linfócitos infiltrando os tumores, composição de crioconservação, e, bolsas de infusão e de armazenamento
|
|
EP3784254A1
(en)
|
2018-04-27 |
2021-03-03 |
Iovance Biotherapeutics, Inc. |
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
US12473532B2
(en)
|
2018-05-10 |
2025-11-18 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
US20200024326A1
(en)
*
|
2018-06-14 |
2020-01-23 |
Nantbio, Inc. |
Tnf-type receptor-ligand fusion proteins and methods
|
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
|
|
CA3112599A1
(en)
|
2018-09-20 |
2020-03-26 |
Iovance Biotherapeutics, Inc. |
Expansion of tils from cryopreserved tumor samples
|
|
JP2022506508A
(ja)
|
2018-11-05 |
2022-01-17 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
Ａｋｔ経路阻害剤を利用したｔｉｌの拡大培養
|
|
WO2020096986A2
(en)
|
2018-11-05 |
2020-05-14 |
Iovance Biotherapeutics, Inc. |
Selection of improved tumor reactive t-cells
|
|
TW202039831A
(zh)
|
2018-11-05 |
2020-11-01 |
美商艾歐凡斯生物治療公司 |
對抗ｐｄ－１抗體呈現難治性之非小細胞肺癌（ｎｓｃｌｃ）病患之治療
|
|
PE20211292A1
(es)
|
2018-11-05 |
2021-07-20 |
Iovance Biotherapeutics Inc |
Procesos para la produccion de linfocitos infiltrantes de tumor y usos de estos en inmunoterapia
|
|
WO2020131547A1
(en)
|
2018-12-19 |
2020-06-25 |
Iovance Biotherapeutics, Inc. |
Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
|
|
WO2020163534A1
(en)
*
|
2019-02-06 |
2020-08-13 |
The Regents Of The University Of California |
Dominant negative cd40l polypeptides
|
|
EP3924507A4
(en)
*
|
2019-02-15 |
2022-11-30 |
Epicypher, Inc. |
QUANTITATIVE IMAGE OF CHROMATIN-ASSOCIATED PROTEINS
|
|
US20220133795A1
(en)
|
2019-03-01 |
2022-05-05 |
Iovance Biotherapeutics, Inc. |
Expansion of Tumor Infiltrating Lymphocytes From Liquid Tumors and Therapeutic Uses Thereof
|
|
US20220177547A1
(en)
*
|
2019-03-07 |
2022-06-09 |
Kyungpook National University Industry-Academic Cooperation Foundation |
Ferritin nanocage for multi-displaying trail trimer and cancer-targeting peptide and use thereof as anticancer agent
|
|
EP3946437B1
(en)
|
2019-03-29 |
2025-11-19 |
H. Lee Moffitt Cancer Center and Research Institute, Inc. |
Ex vivo methods for producing a t cell therapeutic and related compositions and methods
|
|
WO2020232029A1
(en)
|
2019-05-13 |
2020-11-19 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
AU2020301529A1
(en)
|
2019-06-24 |
2022-01-06 |
Universität Stuttgart |
TNFR2 agonists with improved stability
|
|
EP4048295A1
(en)
|
2019-10-25 |
2022-08-31 |
Iovance Biotherapeutics, Inc. |
Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
US20230032934A1
(en)
|
2019-11-27 |
2023-02-02 |
Myst Therapeutics, Llc |
Method of producing tumor-reactive t cell composition using modulatory agents
|
|
WO2021118990A1
(en)
|
2019-12-11 |
2021-06-17 |
Iovance Biotherapeutics, Inc. |
Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
|
|
EP4110799B1
(en)
|
2020-02-27 |
2024-11-06 |
Turnstone Biologics Corp. |
Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof
|
|
CA3177413A1
(en)
|
2020-05-04 |
2021-11-11 |
Michelle SIMPSON-ABELSON |
Selection of improved tumor reactive t-cells
|
|
US20230172987A1
(en)
|
2020-05-04 |
2023-06-08 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
US20230372397A1
(en)
|
2020-10-06 |
2023-11-23 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
WO2022079308A1
(en)
*
|
2020-10-16 |
2022-04-21 |
Institut Pasteur |
Chimeric constructs useful in vaccination and cancer therapy
|
|
KR20230110545A
(ko)
|
2020-11-19 |
2023-07-24 |
칼리버 임뮤노쎄라퓨틱스, 인크. |
종양 미세환경 재형성에 의한 종양용해 면역요법
|
|
WO2022125941A1
(en)
|
2020-12-11 |
2022-06-16 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
|
|
CA3202483A1
(en)
|
2020-12-17 |
2022-06-23 |
Maria Fardis |
Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
|
|
WO2022133149A1
(en)
|
2020-12-17 |
2022-06-23 |
Iovance Biotherapeutics, Inc. |
Treatment of cancers with tumor infiltrating lymphocytes
|
|
US20240299540A1
(en)
|
2021-02-05 |
2024-09-12 |
Iovance Biotherapeutics, Inc. |
Adjuvant therapy for cancer
|
|
CA3210755A1
(en)
|
2021-03-05 |
2022-09-09 |
Kenneth ONIMUS |
Tumor storage and cell culture compositions
|
|
BR112023021665A2
(pt)
|
2021-04-19 |
2023-12-19 |
Iovance Biotherapeutics Inc |
Método para tratar um câncer, e, composição
|
|
TW202305125A
(zh)
|
2021-04-30 |
2023-02-01 |
美商凱立凡爾免疫治療股份有限公司 |
用於經修飾mhc表現之溶瘤病毒
|
|
JP2024519029A
(ja)
|
2021-05-17 |
2024-05-08 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
Ｐｄ－１遺伝子編集された腫瘍浸潤リンパ球及び免疫療法におけるその使用
|
|
MX2023015106A
(es)
*
|
2021-06-17 |
2024-01-22 |
Kalivir Immunotherapeutics Inc |
Proteinas de fusion tnfsf-l y usos de las mismas.
|
|
US20240342285A1
(en)
|
2021-07-28 |
2024-10-17 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
|
|
US20250000903A1
(en)
|
2021-09-24 |
2025-01-02 |
Iovance Biotherapeutics, Inc. |
Expansion processes and agents for tumor infiltrating lymphocytes
|
|
EP4423755A2
(en)
|
2021-10-27 |
2024-09-04 |
Iovance Biotherapeutics, Inc. |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
|
CA3237410A1
(en)
|
2021-11-10 |
2023-05-19 |
Friedrich Graf Finck VON FINCKENSTEIN |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
|
WO2023088889A1
(en)
|
2021-11-16 |
2023-05-25 |
Apogenix Ag |
CD137 ligands
|
|
EP4469066A1
(en)
|
2022-01-28 |
2024-12-04 |
Iovance Biotherapeutics, Inc. |
Tumor infiltrating lymphocytes engineered to express payloads
|
|
EP4507704A1
(en)
|
2022-04-15 |
2025-02-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
|
JP2025523573A
(ja)
|
2022-07-01 |
2025-07-23 |
トランジェーヌ |
サーファクタントタンパク質－ｄとｔｎｆｓｆのメンバーを含んでなる融合タンパク質
|
|
WO2024030758A1
(en)
|
2022-08-01 |
2024-02-08 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
WO2024151885A1
(en)
|
2023-01-13 |
2024-07-18 |
Iovance Biotherapeutics, Inc. |
Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
|
|
WO2025101484A1
(en)
|
2023-11-06 |
2025-05-15 |
Iovance Biotherapeutics, Inc. |
Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
|